Alix-Panabieres: #MDxEU17 Recent work https://t.co/kGJI4kwvPF Look at gene exp profiles cp against HT-29 >2K genes differentially exp
6:19am April 12th 2017 via Hootsuite
Alix-Panabieres: Immunodef SCID mice, BRAF mutant, WT KRAS, stable for 3y, in-vitro/in-vivo testing underway #MDxEU17
6:17am April 12th 2017 via Hootsuite
Alix-Panabieres: Cell lines from CTCs of colorectal cancer hard- liver filters https://t.co/SdsvinQOft https://t.co/ltJBm53JOC #MDxEU17
6:15am April 12th 2017 via Hootsuite
Alix-Panabieres: #MDxEU17 The challenge in CRC - the liver serves as a filter '13 ref https://t.co/HFzJ3sAV7I
6:14am April 12th 2017 via Hootsuite
Alix-Panabieres: Metastasis-competent CTCs. First-done in mice in '13 https://t.co/he8h3TOcfs MDxEU17
6:11am April 12th 2017 via Hootsuite
Catherine Alix-Panabieres (Univ Montpelier FR) Establishment and char of a cel line from human circulating colon cancer cells #MDxEU17
6:10am April 12th 2017 via Hootsuite
Q: 3 mL of plasma, how much input? Jovelet: Get 40uL, use 3uL (less than 1/10th) #MDxEU17
5:38am April 12th 2017 via Hootsuite
Jovelet: R2=0.78 between @iontorrent NGS and dPCR. Concl is better suited for known muts (2h vs 2d, cost and sens.) #MDxEU17
5:36am April 12th 2017 via Hootsuite
Jovelet: Showed 50 to 300d post Rx, 14 pt results of progressive (high or rising AF) or stable disease. Responders very low AF #MDxEU17
5:34am April 12th 2017 via Hootsuite
Jovelet: Day 0 - 29/50 had EGFR act muts, 14/50 had T790M. AFs from 50% down to 1%, 3 not det by NGS, 1 (3% AF) not det by dPCR #MDxEU17
5:33am April 12th 2017 via Hootsuite
Jovelet: EGFR activating Ex19 del, L858R, L861Q, resistance T790M. Of 66pts, 50 had EGFR muts #MDxEU17
5:31am April 12th 2017 via Hootsuite
Jovelet: Shows workflow of Stilla, uses @iontorrent for their NGS-based analysis of same samples. #MDxEU17
5:29am April 12th 2017 via Hootsuite
Celile Jovelet (Gustave Roussy FR) Crystal digital PCR for detection and quantitation of circ. EGFR mutations in advanced NSCLC #MDxEU17
5:28am April 12th 2017 via Hootsuite
Yuzuki: @SeraCare is developing a second iteration of their circulating tumor DNA standards, with better size and usable molecules #MDxEU17
5:15am April 12th 2017 via Hootsuite
Dale Yuzuki (SeraCare MD) Improved material for developing, validating and monitoring liquid biopsy assays #MDxEU17
5:10am April 12th 2017 via Hootsuite
Yuzuki: For ctDNA methods to be comparable, an external reference is required, so consistency in measurements can further the field #MDxEU17
Heitzer: Benchmarks and SOPs are needed 'urgently', mentions CANCER-ID as 'the right way to go', participates in it #MDxEU17
5:01am April 12th 2017 via Hootsuite
Heitzer: PCR artifacts can occur when very low tumor amounts. Concl - monitoring treatment response is possible #MDxEU17
Heitzer: Shows chr12 data pre- and post-treatment with clear amplification signal. '14 PLoS Genet https://t.co/mKb0ogXxd5. #MDxEU17
4:55am April 12th 2017 via Hootsuite
Heitzer: Looking at CRC under anti-EGFR Rx, only wt KRAS. Almost all pts, resistance occurs w/in 3-6 mos, find KRAS ampl #MDxEU17
4:53am April 12th 2017 via Hootsuite
Heitzer: Unanswered question is what is the perfect time-point for blood draw? #MDxEU17
4:52am April 12th 2017 via Hootsuite
Heitzer: Shows unpubl. data of similar data for pr ca pts - Z-score goes from very high to undetectable after tretment. #MDxEU17
4:48am April 12th 2017 via Hootsuite
Heitzer: Shows unpubl data of individual breast cancer pts, looking at ctDNA burden across treatment. Method for high tumor >10% #MDxEU17
4:45am April 12th 2017 via Hootsuite
Heitzer: Shows map of z-score by chr. Reflects degree of aneuploidy. '15 ref https://t.co/lxgwWdkNbL Nice correlation to tumor #MDxEU17
4:44am April 12th 2017 via Hootsuite
Heitzer: mFAST-SeqS is using >20K LINE1 sequences, mapped back, counts/chr arm. See if the numbers differs, z-score calc #MDxEU17
4:42am April 12th 2017 via Hootsuite
Heitzer: With low burden - need to go deep, with knowledge of primary tumor. For Ph II study - go directly to plasma-Seq #MDxEU17
4:41am April 12th 2017 via Hootsuite
Heitzer: Do pre-screening with mFAST-SeqS to est tumor load in plasma. Untargeted assesment of tumor DNA fx #MDxEU17
4:40am April 12th 2017 via Hootsuite
Heitzer: There are clinical situations where highly metastatic cases do not have ctDNA detected. Wanted genome-wide method #MDxEU17
4:39am April 12th 2017 via Hootsuite
Hellen Heitzer (Med Univ Graz Austria): Monitoring treatment response and identification of actionable targets from plasma DNA #MDxEU17
4:37am April 12th 2017 via Hootsuite
Q: PD1/L1 expression heterogeneity? Pantel: Not surprised biomarker studies are not explaining everything; much more to do #MDxEU17
4:36am April 12th 2017 via Hootsuite
Q: Malignant, metastatic potential end-point? Pantel: "Predictions are difficult, particularly for the future." #MDxEU17
4:35am April 12th 2017 via Hootsuite
Pantel: At ASCO, ASCO and AACR presidents will have a session discussing liquid biopsy #MDxEU17
4:32am April 12th 2017 via Hootsuite
Pantel: What we do not know (yet) https://t.co/1kStLZGw1a Comparing CTC and ctDNA in mBC '14 ref https://t.co/mTYSngqJ4L #MDxEU17
4:31am April 12th 2017 via Hootsuite
Pantel: Exosomes are interesting - taken up by recipient cells, can guide organ-spec metastasis '15 ref https://t.co/6iFSypuIlr #MDxEU17
4:29am April 12th 2017 via Hootsuite
Pantel: Hamburg city health study, 45K individuals aged 45-75yo. Collecting samples now. Mentions CANCERID #MDxEU17
4:27am April 12th 2017 via Hootsuite
Pantel: 10% of non-cancer controls had TP53 in this '16 PNAS for ovarian ca #MDxEU17
4:25am April 12th 2017 via Hootsuite
Pantel: Onto matching genotype/phenotype, mentions DEPArray. Early cancer detection: there are tumor-assoc'd mutations in aging #MDxEU17
4:24am April 12th 2017 via Hootsuite
Pantel: But in lung cancer, the number of EGFR mutations known in tissue detected in blood had sens of only 65% #MDxEU17
4:23am April 12th 2017 via Hootsuite
Pantel: Tissue biopsy vs plasma DNA analysis - '14 ref https://t.co/Z49M2iumCr this was for EGFR L858R and T790M, good spec/sens #MDxEU17
4:21am April 12th 2017 via Hootsuite
Pantel: Now looking at AR-V7, CK19 status (unpublished). Mutations relevant to Rx -(moving onto ctDNA) #MDxEU17
4:18am April 12th 2017 via Hootsuite
Pantel: Further characterization, via both EpCAM and Parsortix '16 ref https://t.co/oua7uOTFA5 #MDxEU17
4:17am April 12th 2017 via Hootsuite
Pantel: Blocking Ab - one of the top innovations of the decade. PD-L1 showed in mBC CTCs https://t.co/gr5HbEAOSO #MDxEU17
4:16am April 12th 2017 via Hootsuite
Pantel: CTC characterization is ID of targets, and ID resistance mechanisms. PD1-PD-L1 mediated immune blockade as cancer target #MDxEU17
4:14am April 12th 2017 via Hootsuite
Pantel: 2K pts, analysis of CTCs in EU, of metastatic breast cancer. '14 ref https://t.co/knAAvDdzBE #MDxEU17
Pantel: In Br ca, shows K-M curves, very promising, 'early days'. Monitoring Rx response from '13 NEJM https://t.co/RKe1oi2TNb #MDxEU17
4:12am April 12th 2017 via Hootsuite
Pantel: EpCAM+/CK+ CTCs are assoc' with poor prognosis in advanced cancers. ERA-NET TRANScan for Pr Ca https://t.co/pyO1f6ZbHi #MDxEU17
4:11am April 12th 2017 via Hootsuite
Pantel: Recent review https://t.co/4HE7Skj540 supporting the 'complementary' concept between liquid and invasive biopsy #MDxEU17
4:10am April 12th 2017 via Hootsuite
Pantel: Can get representative information from metastatic cells; CTC/ctDNA a complement to invasive biopsy #MDxEU17
4:07am April 12th 2017 via Hootsuite
Pantel: A growing concetp - across CTC, ctDNA, and exosomes. Needle biopsies are invasive; intra-tumor heterogeneity a problem #MDxEU17
Klaus Pantel (Hamburg-Eppendorf GE) Clinical applications of liquid biopsy - potential and challenges #MDxEU17
4:05am April 12th 2017 via Hootsuite
